APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha 1 Antitrypsin Deficiency Treatment

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Selected research

Industry Growth & Trends

Global Alpha 1 Antitrypsin Deficiency Treatment Industry Growth and Trends Forecast to 2032

29 December 2025104 pages

Choose your research edition.

Industry ResearchAlpha 1 Antitrypsin Deficiency Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha 1 Antitrypsin Deficiency Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Alpha 1 Antitrypsin Deficiency Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

According to APO Research, the global Alpha 1 Antitrypsin Deficiency Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Alpha 1 Antitrypsin Deficiency Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Alpha 1 Antitrypsin Deficiency Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Alpha 1 Antitrypsin Deficiency Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Alpha 1 Antitrypsin Deficiency Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Alpha 1 Antitrypsin Deficiency Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Alpha 1 Antitrypsin Deficiency Treatment Market by Company

Pfizer

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Teva Pharmaceutical Industries

Takeda

Baxter

Grifols

CSL Behring

Kamada Ltd

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

Alpha 1 Antitrypsin Deficiency Treatment Segment by Indication

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Other

Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users

COPD

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Alpha 1 Antitrypsin Deficiency Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2021-2026) Table 4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2027-2032) Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2021-2026) & (US$ Million) Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Indication (2021-2026) Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecasted by Indication (2027-2032) & (US$ Million) Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share Forecasted by Indication (2027-2032) Table 11. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026) & (US$ Million) Table 12. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2027-2032) & (US$ Million) Table 13. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026) & (US$ Million) Table 14. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2027-2032) & (US$ Million) Table 15. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026) & (US$ Million) Table 16. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2027-2032) & (US$ Million) Table 17. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026) & (US$ Million) Table 18. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2027-2032) & (US$ Million) Table 19. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026) & (US$ Million) Table 20. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2027-2032) & (US$ Million) Table 21. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2021-2026) & (US$ Million) Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by End Users (2021-2026) Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecasted by End Users (2027-2032) & (US$ Million) Table 25. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share Forecasted by End Users (2027-2032) Table 26. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026) & (US$ Million) Table 27. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2027-2032) & (US$ Million) Table 28. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026) & (US$ Million) Table 29. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2027-2032) & (US$ Million) Table 30. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026) & (US$ Million) Table 31. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2027-2032) & (US$ Million) Table 32. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026) & (US$ Million) Table 33. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2027-2032) & (US$ Million) Table 34. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026) & (US$ Million) Table 35. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2027-2032) & (US$ Million) Table 36. Alpha 1 Antitrypsin Deficiency Treatment Industry Trends Table 37. Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers Table 38. Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges Table 39. Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints Table 40. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Alpha 1 Antitrypsin Deficiency Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Alpha 1 Antitrypsin Deficiency Treatment Key Company Headquarters & Area Served Table 44. Global Alpha 1 Antitrypsin Deficiency Treatment Company, Product Type & Application Table 45. Global Alpha 1 Antitrypsin Deficiency Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 52. Pfizer Recent Development Table 53. GlaxoSmithKline Company Information Table 54. GlaxoSmithKline Business Overview Table 55. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 57. GlaxoSmithKline Recent Development Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 62. AstraZeneca Recent Development Table 63. Boehringer Ingelheim Company Information Table 64. Boehringer Ingelheim Business Overview Table 65. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 67. Boehringer Ingelheim Recent Development Table 68. Teva Pharmaceutical Industries Company Information Table 69. Teva Pharmaceutical Industries Business Overview Table 70. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 72. Teva Pharmaceutical Industries Recent Development Table 73. Takeda Company Information Table 74. Takeda Business Overview Table 75. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 77. Takeda Recent Development Table 78. Baxter Company Information Table 79. Baxter Business Overview Table 80. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 82. Baxter Recent Development Table 83. Grifols Company Information Table 84. Grifols Business Overview Table 85. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 87. Grifols Recent Development Table 88. CSL Behring Company Information Table 89. CSL Behring Business Overview Table 90. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 92. CSL Behring Recent Development Table 93. Kamada Ltd Company Information Table 94. Kamada Ltd Business Overview Table 95. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 97. Kamada Ltd Recent Development Table 98. Chiesi Pharmaceuticals Company Information Table 99. Chiesi Pharmaceuticals Business Overview Table 100. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 102. Chiesi Pharmaceuticals Recent Development Table 103. Kedrion Group Company Information Table 104. Kedrion Group Business Overview Table 105. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 107. Kedrion Group Recent Development Table 108. Vertex Pharmaceuticals Company Information Table 109. Vertex Pharmaceuticals Business Overview Table 110. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 112. Vertex Pharmaceuticals Recent Development Table 113. ProMetic Life Sciences Company Information Table 114. ProMetic Life Sciences Business Overview Table 115. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 117. ProMetic Life Sciences Recent Development Table 118. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) & (US$ Million) Table 120. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2026) Table 121. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Country (2027-2032) Table 123. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) & (US$ Million) Table 125. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2026) Table 126. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) & (US$ Million) Table 130. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2026) Table 131. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Country (2027-2032) Table 133. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2026) Table 136. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Country (2027-2032) Table 138. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2026) Table 141. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Country (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Alpha 1 Antitrypsin Deficiency Treatment Product Image Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2021-2032) Figure 7. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Augmentation Therapy Image Figure 13. Global Augmentation Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Cystic Fibrosis(CF) Image Figure 15. Global Cystic Fibrosis(CF) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Non-CF Bronchiectasis(NCFB) Image Figure 17. Global Non-CF Bronchiectasis(NCFB) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Diabetes Image Figure 19. Global Diabetes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Other Image Figure 21. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type 2025 VS 2032 Figure 24. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2021-2032) Figure 25. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2021-2032) Figure 27. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2021-2032) Figure 29. COPD Image Figure 30. Global COPD Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Cystic Fibrosis(CF) Image Figure 32. Global Cystic Fibrosis(CF) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Non-CF Bronchiectasis(NCFB) Image Figure 34. Global Non-CF Bronchiectasis(NCFB) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Diabetes Image Figure 36. Global Diabetes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application 2025 VS 2032 Figure 39. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2032) Figure 40. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2032) Figure 42. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 49. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 52. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 55. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 58. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
  • Other
Applications
  • COPD
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
Companies covered
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries
  • Takeda
  • Baxter
  • Grifols
  • CSL Behring
  • Kamada Ltd
  • Chiesi Pharmaceuticals
  • Kedrion Group
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  8. 1.5.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (2021-2032)
2 Alpha 1 Antitrypsin Deficiency Treatment Market by Indication
  1. 2.1 Type Introduction
  2. 2.1.1 Augmentation Therapy
  3. 2.1.2 Cystic Fibrosis(CF)
  4. 2.1.3 Non-CF Bronchiectasis(NCFB)
  5. 2.1.4 Diabetes
  6. 2.1.5 Other
  7. 2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication
  8. 2.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by Indication (2021-2032)
  9. 2.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size Review by Indication (2021-2026)
  10. 2.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecasted by Indication (2027-2032)
  11. 2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions
  12. 2.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026)
  13. 2.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026)
  14. 2.3.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026)
  15. 2.3.4 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026)
  16. 2.3.5 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by Indication (2021-2026)
3 Alpha 1 Antitrypsin Deficiency Treatment Market by End Users
  1. 3.1 Type Introduction
  2. 3.1.1 COPD
  3. 3.1.2 Cystic Fibrosis(CF)
  4. 3.1.3 Non-CF Bronchiectasis(NCFB)
  5. 3.1.4 Diabetes
  6. 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users
  7. 3.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by End Users (2021-2032)
  8. 3.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size Review by End Users (2021-2026)
  9. 3.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecasted by End Users (2027-2032)
  10. 3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions
  11. 3.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026)
  12. 3.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026)
  13. 3.3.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026)
  14. 3.3.4 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026)
  15. 3.3.5 Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Breakdown by End Users (2021-2026)
4 Global Market Dynamics
  1. 4.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
  2. 4.2 Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers
  3. 4.3 Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges
  4. 4.4 Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Alpha 1 Antitrypsin Deficiency Treatment Revenue (2021-2026)
  2. 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Alpha 1 Antitrypsin Deficiency Treatment Company, Product Type & Application
  5. 5.5 Global Alpha 1 Antitrypsin Deficiency Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Alpha 1 Antitrypsin Deficiency Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 GlaxoSmithKline
  8. 6.2.1 GlaxoSmithKline Company Information
  9. 6.2.2 GlaxoSmithKline Business Overview
  10. 6.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  12. 6.2.5 GlaxoSmithKline Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Boehringer Ingelheim
  20. 6.4.1 Boehringer Ingelheim Company Information
  21. 6.4.2 Boehringer Ingelheim Business Overview
  22. 6.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  24. 6.4.5 Boehringer Ingelheim Recent Developments
  25. 6.5 Teva Pharmaceutical Industries
  26. 6.5.1 Teva Pharmaceutical Industries Company Information
  27. 6.5.2 Teva Pharmaceutical Industries Business Overview
  28. 6.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  30. 6.5.5 Teva Pharmaceutical Industries Recent Developments
  31. 6.6 Takeda
  32. 6.6.1 Takeda Company Information
  33. 6.6.2 Takeda Business Overview
  34. 6.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  36. 6.6.5 Takeda Recent Developments
  37. 6.7 Baxter
  38. 6.7.1 Baxter Company Information
  39. 6.7.2 Baxter Business Overview
  40. 6.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  42. 6.7.5 Baxter Recent Developments
  43. 6.8 Grifols
  44. 6.8.1 Grifols Company Information
  45. 6.8.2 Grifols Business Overview
  46. 6.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  48. 6.8.5 Grifols Recent Developments
  49. 6.9 CSL Behring
  50. 6.9.1 CSL Behring Company Information
  51. 6.9.2 CSL Behring Business Overview
  52. 6.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  54. 6.9.5 CSL Behring Recent Developments
  55. 6.10 Kamada Ltd
  56. 6.10.1 Kamada Ltd Company Information
  57. 6.10.2 Kamada Ltd Business Overview
  58. 6.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  60. 6.10.5 Kamada Ltd Recent Developments
  61. 6.11 Chiesi Pharmaceuticals
  62. 6.11.1 Chiesi Pharmaceuticals Company Information
  63. 6.11.2 Chiesi Pharmaceuticals Business Overview
  64. 6.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  66. 6.11.5 Chiesi Pharmaceuticals Recent Developments
  67. 6.12 Kedrion Group
  68. 6.12.1 Kedrion Group Company Information
  69. 6.12.2 Kedrion Group Business Overview
  70. 6.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  72. 6.12.5 Kedrion Group Recent Developments
  73. 6.13 Vertex Pharmaceuticals
  74. 6.13.1 Vertex Pharmaceuticals Company Information
  75. 6.13.2 Vertex Pharmaceuticals Business Overview
  76. 6.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  78. 6.13.5 Vertex Pharmaceuticals Recent Developments
  79. 6.14 ProMetic Life Sciences
  80. 6.14.1 ProMetic Life Sciences Company Information
  81. 6.14.2 ProMetic Life Sciences Business Overview
  82. 6.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  84. 6.14.5 ProMetic Life Sciences Recent Developments
7 North America
  1. 7.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst